Study on Nivolumab, Relatlimab, and Bevacizumab for Advanced Liver Cancer
Sponsor: Bristol-Myers Squibb
ClinicalTrials ID:NCT05337137
This clinical trial is testing a new combination of three drugs—Nivolumab, Relatlimab, and Bevacizumab—to see if it is safe and effective for people with advanced liver cancer who have not yet received treatment. The study compares this combination to a two-drug treatment of Nivolumab and Bevacizumab.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The aim of this study is to determine if a new treatment using three drugs—Nivolumab, Relatlimab, and Bevacizumab—can safely and effectively treat advanced liver cancer, specifically hepatocellular carcinoma (HCC), in patients who have not received prior treatment for their advanced cancer. The study will compare the results of this three-drug combination to a treatment using only Nivolumab and Bevacizumab.
Eligibility Criteria
Inclusion Criteria
- Have a confirmed diagnosis of advanced or metastatic liver cancer (hepatocellular carcinoma).
- Have not received any prior systemic treatment for advanced liver cancer. Previous immunotherapy is allowed if the cancer returned at least 6 months after completing treatment and the case is reviewed by the medical team.
- Have a Child-Pugh score of 5 or 6, indicating good liver function.
- Be in good overall health with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
Exclusion Criteria
- Have a specific type of liver cancer known as fibrolamellar, sarcomatoid, or mixed cholangiocarcinoma and hepatocellular carcinoma.
- Have had a previous stem cell or organ transplant.
- Have untreated, symptomatic cancer that has spread to the brain or spinal cord.
- Have significant fluid buildup in the abdomen (ascites) that requires ongoing treatment or current treatment.
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.